Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 6427878

Drug Profile

PF 6427878

Alternative Names: PF-06427878; PF-6427878

Latest Information Update: 08 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 30 Jan 2018 Discontinued - Phase-I for Hyperlipidaemia (In volunteers) in United Kingdom (IV) (Pfizer pipeline, March 2018)
  • 30 Jan 2018 Discontinued - Phase-I for Hyperlipidaemia (In volunteers) in USA, Belgium (PO) (Pfizer pipeline, March 2018)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top